A note on air temperature lapse rates on Mount Wellington, Tasmania

Temperature lapse rates are derived from field measurements taken on Mt Wellington over a one year period. The results are compared with regional lapse rates for the state. The agreement is best with maximum temperatures in winter and minimum temperatures in summer. The agreement is poor with other combinations. This is due to oceanic and continental effects

Use of insulin glargine and cancer incidence in Scotland: a study from the

Abstract Aims/hypothesis The aim of the present study was to examine whether patients with diabetes in Scotland using insulin glargine have a greater cancer risk than patients using other types of insulin. Methods We used a nationwide diabetes clinical database that covers the majority of the Scottish population with diagnosed diabetes, and examined patients with diabetes who were exposed to any insulin therapy between 1 January 2002 and 31 December 2005. Among these we defined a fixed cohort based on exposure during a 4 month period in 2003 (n=36,254, in whom 715 cases of cancer occurred) and a cohort of new insulin users across the period (n=12,852 in whom 381 cancers occurred). Records from these cohorts were linked to cancer registry data up to the end of 2005. We used Cox proportional hazards models for survival analyses. Results Those receiving any insulin glargine (n=3,959) had the same incidence rate for all cancers as those not receiving insulin glargine (HR 1.02, 95% CI 0.77-1.36, p=0.9 in the fixed cohort) The subset of patients using insulin glargine alone (n=447) had a significantly higher incidence of all cancers than those using other insulins only (n=32,295) (HR 1.55, 95% CI 1.01-2.37, p=0.045), and those using insulin glargine with other insulins (n=3,512) had a slightly lower incidence (HR 0.81, 95% CI 0.55-1.18, p=0.26). There were important differences in baseline characteristics between these three groups, although the risk ratios were broadly unaltered on adjustment for these. Overall, there was no increase in breast cancer rates associated with insulin glargine use (HR 1.49, 95% CI 0.79-2.83, though insulin glargine only users had a higher rate than those using non-glargine insulin only (HR 3.39, 95% CI 1.46-7.85, p=0.004). Among type 2 diabetic incident insulin users, no significant difference between the three groups was observed with respect to all cancer or breast cancer. All the above HRs are adjusted for age, calendar time prior cancer and type of diabetes, as appropriate, and are stratified according to sex. Conclusions/interpretation Overall, insulin glargine use was not associated with an increased risk of all cancers or site-specific cancers in Scotland over a 4 year time frame. Given the overall data, we consider the excess of cases of all cancers and breast cancer in the subgroup of insulin glargine only users to more likely reflect allocation bias rather than an effect of insulin glargine itself

Biomarkers of diabetic kidney disease.

Diabetic kidney disease (DKD) remains one of the leading causes of reduced lifespan in diabetes. The quest for both prognostic and surrogate endpoint biomarkers for advanced DKD and end-stage renal disease has received major investment and interest in recent years. However, at present no novel biomarkers are in routine use in the clinic or in trials. This review focuses on the current status of prognostic biomarkers. First, we emphasise that albuminuria and eGFR, with other routine clinical data, show at least modest prediction of future renal status if properly used. Indeed, a major limitation of many current biomarker studies is that they do not properly evaluate the marginal increase in prediction on top of these routinely available clinical data. Second, we emphasise that many of the candidate biomarkers for which there are numerous sporadic reports in the literature are tightly correlated with each other. Despite this, few studies have attempted to evaluate a wide range of biomarkers simultaneously to define the most useful among these correlated biomarkers. We also review the potential of high-dimensional panels of lipids, metabolites and proteins to advance the field, and point to some of the analytical and post-analytical challenges of taking initial studies using these and candidate approaches through to actual clinical biomarker use

A genome-wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain

BACKGROUND: Neuropathic pain, caused by a lesion or a disease affecting the somatosensory system, is one of the most common complications in diabetic patients. The purpose of this study is to identify genetic factors contributing to this type of pain in a general diabetic population. METHOD: We accessed the Genetics of Diabetes Audit and Research Tayside (GoDARTS) datasets that contain prescription information and monofilament test results for 9439 diabetic patients, among which 6927 diabetic individuals were genotyped by Affymetrix SNP6.0 or Illumina OmniExpress chips. Cases of neuropathic pain were defined as diabetic patients with a prescription history of at least one of five drugs specifically indicated for the treatment of neuropathic pain and in whom monofilament test result was positive for sensory neuropathy in at least one foot. Controls were individuals who did not have a record of receiving any opioid analgesics. Imputation of non‐genotyped SNPs was performed by IMPUTE2, with reference files from 1000 Genomes Phase I datasets. RESULTS: After data cleaning and relevant exclusions, imputed genotypes of 572 diabetic neuropathic pain cases and 2491 diabetic controls were used in the Fisher's exact test. We identified a cluster in the Chr8p21.3, next to GFRA2 with a lowest p‐value of 1.77 × 10(−7) at rs17428041. The narrow‐sense heritability of this phenotype was 11.00%. CONCLUSION: This genome‐wide association study on diabetic neuropathic pain suggests new evidence for the involvement of variants near GFRA2 with the disorder, which needs to be verified in an independent cohort and at the molecular level

On-Orbit Health Check of Hubble Space Telescope Nickel-Hydrogen Batteries

The Hubble Space Telescope is a one-of-a-kind spacecraft that pushes technology to its limits. Housing an 8-foot (2.4 meter) mirror and several sophisticated cameras and detectors the telescope is the largest orbital astronomy observatory ever placed in space. It has two modules each containing three 88 Ah NiH2 batteries (six total). Reconditioning has traditionally been used as a means of maintaining the performance of normal cells and batteries. This paper describes the objective, procedure, and results of a reconditioning processes that used to improve the performance of an HST nickel-hydrogen batteries

Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland

Objective: To investigate the association of severe coronavirus disease 2019 (COVID-19) in patients with inflammatory rheumatic diseases (IRDs) treated with immunosuppressive drugs. Method: A list of 4633 patients on targeted – biological or targeted synthetic – DMARDs in March 2020 was linked to a case– control study that includes all cases of COVID-19 in Scotland. Results: By 22 November 2021, 433 of the 4633 patients treated with targeted DMARDS had been diagnosed with COVID-19, of whom 58 had been hospitalized. With all those in the population not on DMARDs as the reference category, the rate ratio for hospitalized COVID-19 associated with DMARD treatment was 2.14 [95% confidence interval (CI) 2.02–2.26] in those on conventional synthetic (cs) DMARDs, 2.01 (95% CI 1.38–2.91) in those on tumour necrosis factor (TNF) inhibitors as the only targeted agent, and 3.83 (95% CI 2.65–5.56) in those on other targeted DMARDs. Among those on csDMARDs, rate ratios for hospitalized COVID-19 were lowest at 1.66 (95% CI 1.51–1.82) in those on methotrexate and highest at 5.4 (95% CI 4.4–6.7) in those on glucocorticoids at an average dose > 10 mg/day prednisolone equivalent. Conclusion: The risk of hospitalized COVID-19 is elevated in IRD patients treated with immunosuppressive drugs compared with the general population. Of these drugs, methotrexate, hydroxychloroquine, and TNF inhibitors carry the lowest risk. The highest risk is associated with prednisolone. A larger study is needed to estimate reliably the risks associated with each class of targeted DMAR

How old is the Tasmanian cultural landscape? a test of landscape openness using quantitative land-cover reconstructions

Aim: To test competing hypotheses about the timing and extent of Holocene landscape opening using pollen-based quantitative land-cover estimates. Location: Dove Lake, Tasmanian Wilderness World Heritage Area, Australia. Methods: Fossil pollen data were incorporated into pollen dispersal models and corrected for differences in pollen productivity among key plant taxa. Mechanistic models (REVEALS-Regional Estimates of VEgetation Abundance from Large Sites) employing different models for pollen dispersal (Gaussian plume and Lagrangian stochastic models) were evaluated and applied in the Southern Hemisphere for the first time. Results: Validation of the REVEALS model with vegetation cover data suggests an overall better performance of the Lagrangian stochastic model. Regional land-cover estimates for forest and non-forest plant taxa show persistent landscape openness throughout the Holocene (average landscape openness similar to 50%). Gymnoschoenus sphaerocephalus, an indicator of moorland vegetation, shows higher values during the early Holocene (11.7-9 ka) and declines slightly through the mid-Holocene (9-4.5 ka) during a phase of partial landscape afforestation. Rain forest cover reduced (from similar to 40% to similar to 20%) during the period between 4.2-3.5 ka. Main conclusions: Pollen percentages severely under-represent landscape openness in western Tasmania and this bias has fostered an over-estimation of Holocene forest cover from pollen data. Treeless vegetation dominated Holocene landscapes of the Dove Lake area, allowing us to reject models of landscape evolution that invoke late-Holocene replacement of a rain forest-dominated landscape by moorland. Instead, we confirm a model of Late Pleistocene inheritance of open vegetation. Rapid forest decline occurred after c.4 ka, likely in response to regional moisture decline.Australian Research Council; AINSE AWARD [ALNGRA16024]; AINSE PGRA scholarship [12039]info:eu-repo/semantics/publishedVersio